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average total episode costs were found in the Northeast region
and were $856.50. Average outpatient costs in the Northeast
region were the highest in the country at $377.64—the range for
other regions was $240.70-$285.93. CONCLUSION: Much
diversity exists in the cost of treating acne across different seg-
ments of the United States. Future research should be done to
determine what the underlying factors are when accounting for
the discrepancies in cost per episode of acne.
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OBJECTIVE: To determine the most cost-effective Wet AMD
treatment alternative in Mexico. METHODS: A decision tree
with Bayesian approach and a Markov chain considering the
probabilities of increasing, decreasing or maintaining visual
acuity (VA) through eight health states based on VA from 20/20
to 20/400 due to the use of a pharmacological alternative, with a
time horizon of 5 years and institutional perspective, were per-
formed. The discounting rate was three percent for costs and
beneﬁts. Adverse events and their treatment costs, for every
alternative were considered; costs, beneﬁts and probabilities of
transition data were estimated from the meta-analysis with avail-
able published literature, including the MARINA and ANCHOR
studies, validated by a panel of Mexican experts through the
Delphi technique. Study comparators examined were Ranibi-
zumab (RAN), photodynamic therapy with Verteporﬁn (PDTV),
pegaptanib sodium (PEG) and standard care (STD). Sensitivity
analysis was one-way and probabilistic (acceptability curve,
analysis of components for the ellipse method). RESULTS:
Patients using Ranibizumab get more beneﬁts (RAN = 2.71
QALY; PDTV = 2.03 QALY; PEG = 1.89 QALY; STD = 1.78
QALY), with the lowest total cost per treatment (RAN =
$43,984 USD; STD = $63,531 USD; PDTV = $83,546 USD;
PEG = $92,247 USD) and the lowest cost per QALY (RAN =
$16,257 USD/QALY; STD = $35,749 USD/QALY; PDTV =
$41,074 USD/QALY; PEG = $48,263 USD/QALY). Incremental
analysis showed Ranibizumab to be the dominant alternative.
Net beneﬁts are greater with Ranibizumab independent of will-
ingness to pay. Acceptability curves showed absolute superiority
for Ranibizumab. The conﬁdence interval of 95% with the ellipse
method showed Ranibizumab to be dominant in 95% of the
cases with a willingness to pay of $924USD. The sensitivity
analysis on efﬁciency and costs of Ranibizumab in an interval of
50%, was robust with the base analysis. CONCLUSION:
Ranibizumab is the most cost-effective Wet AMD treatment
alternative; it offers the greatest beneﬁts with the lowest cost.
Sensitivity analyses showed the robustness of the base study.
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OBJECTIVE: Measure incremental cost-utility and budget
impact of etanercept vs. inﬂiximab in moderate-to-severe PSO
with >10% body surface area involvement. METHODS: We
used a Markov decision analysis to compare 2 strategies for PSO:
etanercept label dose (50 mg BIW x12 wks, then 25 mg BIW);
and inﬂiximab label dose (5 mg/kg IV at wks 0, 2, and 6, then
5mg/kg Q8W). We derived 60 probability estimates through
systematic review of the literature and labels, varying each of
these estimates in each sensitivity analysis. We adopted an MCO
payer’s perspective, and included cost estimates for a compre-
hensive list of related resources as determined by Medicare and
the Red Book. Qulaity-adjusted life-years (QALYs) were esti-
mated by applying utilities from the literature to reported efﬁcacy
as measured by PASI scores. We calculated the incremental cost
per QALY gained and incremental per-member per month
(PMPM) budget impact in a hypothetical MCO of 1 million lives
(assuming a 1% prevalence of moderate-to-severe PSO). We dis-
counted costs and effects at 3% per year over a 2-year time
horizon. RESULTS: In the base-case analysis, etanercept yielded
1.68 QALYs at a total cost of $28,442 over the 2-year horizon,
and inﬂiximab yielded 1.78 QALYs at a cost of $49,906. Com-
pared to etanercept, inﬂiximab cost an incremental $214,640/
QALY-gained. In sensitivity analysis, inﬂiximab dominated
etanercept when the cost of inﬂiximab fell by 55% (from $691 to
$312 per 100 mg vial), or when the cost of etanercept increased
83% (from $187 to $342 per 25 mg vial). In budget impact
modeling, inﬂiximab cost an incremental $8.94 PMPM vs. etan-
ercept. CONCLUSION: Decision analysis was used to model
relative cost-utility and budget impact of biologic therapies in
PSO—a chronic health condition. The incremental cost and
budget impact of inﬂiximab vs etanercept exceeds standard
benchmarks in the absence of comparative effectiveness from
head to head trials.
SENSORY SYSTEMS DISORDERS—
Patient-Reported Outcomes
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OBJECTIVE: To evaluate persistence among glaucoma patients
with prostaglandin therapy during the ﬁrst therapy year.
METHODS: Patients with latanoprost (LAT), bimatoprost
(BIM), or travoprost (TRAV) dispensed during January 1, 2004–
December 31, 2004 were screened for inclusion (Ingenix
managed care database). Index agent = ﬁrst agent ﬁlled; index
date = ﬁll date; follow-up = 358 days. Patients excluded if:
age < 40 years; not continuously enrolled for 180 days before/
358 days after index date; had ocular hypotensive dispensed or
had no glaucoma diagnosis within 180 days before index date.
First year persistence measures: whether last ﬁll had sufﬁcient
days supply to achieve medication possession at year’s end;
number of days for which index agent was available (days
covered). Possible inconsistencies between quantity dispensed
and reported days supply addressed by multiplying claimed days
supply with alternative measures from the literature. Models of
associations between index agent and medication possession
(logistic regression) and days covered (linear regression) were
adjusted for gender, age, and previous ocular hypertension diag-
nosis. RESULTS: A total of 7783 patients met inclusion criteria
(LAT, n = 4994; BIM, n = 1464; TRAV, n = 1415). Overall medi-
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cation possession was 28% and number of days covered was 131
using unadjusted days supply estimate. Compared to LAT, odds
of achieving medication possession at year’s end were 26%–34%
lower for BIM and 34%–36% lower for TRAV (p  0.001 for all
comparisons for each imputation). Days covered were 21–29
days lower for BIM and 33–42 days lower for TRAV (p  0.001
for all comparisons). Failure to reﬁll a 2.5 mL size bottle within
the ﬁrst 90 days had 90%–99% speciﬁcity for predicting < 75%
days covered. CONCLUSION: Persistence with ocular prostag-
landins remains a concern. LAT users were more likely to achieve
medication possession and had more days covered during the
ﬁrst therapy year than those treated with BIM or TRAV. Failure
to reﬁll the index agent within the initial 90 days predicted poor
persistence.
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OBJECTIVE: To examine the relationship between distance
visual acuity (DVA) and self-reported vision-related quality of life
in NV-AMD subjects. METHODS: Baseline data from 113 sub-
jects completing 30 weeks in the PERSPECTIVES study, a multi-
center, multi-national 102-week clinical trial for the treatment of
NV-AMD, were reviewed. Vision function of the better-seeing
eye based on DVA (ETDRS letters at 2m), near vision (Bailey-
Lovie logMAR scores at 25cm), reading speed (words/minute at
25cm), and contrast sensitivity (Pelli-Robson logMAR score at
1m) were all measured. Vision-related quality of life (VR-QOL)
was collected using the National Eye Institute Visual Functioning
Questionnaire 25 (NEI-VFQ). Correlations were tested using
Pearson’s R, a = 0.05. RESULTS: Subject mean age was 74.0
years (8.0); 67 (59%) were female; and 109 (97%) were white.
DVA was signiﬁcantly correlated with the three clinical measures
of vision function (p < 0.001). DVA was also correlated with the
NEI-VFQ Distance Vision domain (p = 0.011) but not signiﬁ-
cantly associated with the Near Vision domain (p = 0.057). With
the exception of driving and color vision (p = 0.426 and
p = 0.135), the remaining domain scores were signiﬁcantly cor-
related with the DVA measure (range p = 0.029 to p = 0.001).
CONCLUSION: Some differences in self-reported VR-QOL can
be explained by DVA, while other effects on vision functioning
are less clear. Therefore, it may be preferable to use more than
one measure of vision function when assessing treatment effects.
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OBJECTIVE: To evaluate the effects of ustekinumab on disease
speciﬁc HRQoL in psoriasis patients. METHODS: A total of 765
patients were enrolled in the PHOENIX I study. Patients were
randomized 1:1:1 to receive placebo, ustekinumab 45 mg, or
ustekinumab 90 mg. In the ustekinumab groups,patients received
treatment at weeks 0,4,16, and every 12 weeks thereafter.
Patients randomized to placebo at baseline crossed-over to
receive either 45 mg or 90 mg of ustekinumab at week 12.
Disease speciﬁc HRQoL was assessed using the Dermatology
Life Quality Index (DLQI). RESULTS: Baseline DLQI scores
were similar among treatment groups. The baseline mean
(median) total DLQI score was 11.5 (10.0). At week 2, the
combined ustekinumab group had signiﬁcantly greater improve-
ments (p < 0.001) from baseline in DLQI scores compared to the
placebo group. All placebo-treated patients crossed over to
receive ustekinumab at Week 12 and had comparable DLQI
improvements to the groups originally randomized to receive
ustekinumab. The mean (median) change from baseline score to
week 12 was –8.0 (-6.0) for the 45 mg group and –8.7 (-7.0) for
the 90 mg group, compared with –0.6 (0.0) for the placebo
group. At week 12, the proportion of patients who achieved a
clinically meaningful improvement (decrease of 5 or more points;
Kimball et al, 2004) was 64.6% in the 45 mg group and 71.1%
in the 90 mg group, compared to 17.9% in the placebo group.
Improvements were also demonstrated by the statistically signiﬁ-
cant proportion of patients in the 45 and 90 mg ustekinumab
groups who achieved a DLQI of 0 (32.7% and 34.0%, respec-
tively), as compared to the proportion of patients in the placebo
group (0.8%). CONCLUSION: Treatment with ustekinumab
45 mg or 90 mg resulted in signiﬁcantly improved disease speciﬁc
HRQoL compared with placebo in patients with moderate to
severe psoriasis, as measured by the DLQI.
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OBJECTIVE: To report the impact of ustekinumab on quality of
life(QOL)in psoriasis. METHODS: PHOENIX 2 was a multi-
center,randomized, double-blind, placebo-controlled, trial in
which 1230 psoriasis patients were randomized to receive sub-
cutaneously administered ustekinumab (45or 90 mg 4 weeks
apart, then q12 weeks thereafter) or placebo. Patients changed to
receive 45 or 90 mg ustekinumab at Weeks 12 and 16. Impact on
QOL, anxiety, depression, job performance, and work produc-
tivity were assessed using the Dermatology Life Quality Index
(DLQI), Hospital Anxiety and Depression Scale (HADS), and
Work Limitations Questionnaire(WLQ). RESULTS: DLQI
improvements from baseline were apparent by Week 4 (6.9 for
45 mg and 7.0 for 90 mg versus 1.4 for placebo; each p < 0.001
versus placebo). At Week 12, improvement in DLQI was 9.3 and
10.0 in the 45 and 90 mg groups, compared to 0.5 for place-
bo(each p < 0.001 versus placebo). DLQI improvement was
maintained through Week 24 (9.5 in 45 mg group and 10.3 in
90 mg group). Patients randomized to placebo experienced
improvements in DLQI 12 weeks after changing to ustekinumab.
At Week 12, 36.7%, and 39.1% of patients receiving 45 and
90mg, achieved a DLQI score of 0, indicating no impact of the
disease on patients’ QOL, compared with 1.0% receiving place-
bo(each p < 0.001 versus placebo). At Week 12, 71.8% of
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